Supriya Lifescience Ltd - 543434 - Announcement Under Regulation 30 (LODR) - Updates
The European Directorate for the Quality of Medicines and HealthCare (EDQM) has granted Certification of Suitability (CEP) for Diphenhydramine Hydrochloride, API in Anti-Histamine therapy. This will be an added advantage for Supriya Lifescience Ltd. in the European market. Global demand for Diphenhydramine Hydrochloride is 1850 tons, of which major demand is in the regulated markets.
Supriya Lifescience stock tumbles as CEO resigns
The Board simultaneously approved the appointment of Rajeev Kumar Jain as Chief Executive Officer and Key Managerial Personnel of the Company, who will be joining on October 3, 2022. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the relevant provisions of the SEBI Listing Regulations, we would like to inform you that the officials of our Company, Supriya Lifescience Limited ('Company') will be interacting with Analyst/Institutional Investors on September 28, 2022 via in person meeting. Supriya Lifescience Ltd - 543434 - Appointment Of Chief Executive Officer & Key Managerial Personnel
The Board has in its meeting held today i.e. September 27, 2022 approved the appointment of Mr. Rajeev Kumar Jain as Chief Executive Officer and Key Managerial Personnel of the Company, who will be joining on October 3, 2022 to take Supriya on the next phase of its growth journey. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Resignation of Chief Executive Officer (CEO)
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Dr. Shireesh Ambhaikar, Chief Executive Officer and a Key Managerial Personnel of the company, has resigned from the position due to his personal reasons and requested, inter alia, for acceptance of his resignation and relieving him by September 30, 2022 and which has been accepted by the Board in its meeting held today i.e. September 27, 2022. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the relevant provisions of the SEBI Listing Regulations, we would like to inform you that the officials of our Company, Supriya Lifescience Limited ('Company') will be interacting with Analyst/Institutional Investors on September 27, 2022 via video conference and in person meeting. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the relevant provisions of the SEBI Listing Regulations, we would like to inform you that the officials of our Company, Supriya Lifescience Limited ('Company') will be interacting with Analyst/Institutional Investors on September 26, 2022 via in person meeting. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the relevant provisions of the SEBI Listing Regulations, we would like to inform you that the officials of our Company, Supriya Lifescience Limited ('Company') will be interacting with Analyst/Institutional Investors on September 21, 2022 via in person meeting. Supriya Lifescience Ltd - 543434 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Supriya Lifescience Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, it is hereby informed that the officials of Supriya Lifescience Limited ('Company') had attended the Motilal Oswal Annual Global Investor Conference on September 19, 2022 physically.